Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Monolithic Power Systems Inc (MPWR) vs Zoetis Inc (ZTS) Price & Performance

Monolithic Power Systems IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Monolithic Power Systems Inc vs Zoetis Inc — how do they compare? Monolithic Power Systems Inc trades at $1,397.04 (market cap $67.32B), while Zoetis Inc trades at $73.5 (market cap $30.20B). The key difference: Monolithic Power Systems Inc is far larger — about 2.2× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Zoetis Inc for 70 Days on average.

MPWRZTS
Market Cap
$67.32B$30.20B
Volume
826,9606,175,327
Sector
TechnologyHealth
52-Week High
$1.69K$147.53
52-Week Low
$856.96$69.09
Typical Hold Time
25 Days70 Days
Enterprise Value
$65.92B$37.76B
Dividend Yield
0.58%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Monolithic Power Systems Inc

MPWR trades at $1,425.98, down 3.24% today but maintains strong technical momentum with bullish moving averages and key support at $1,417. The company demonstrates robust fundamentals with 24.5% net margins and consistent earnings beats, while expanding manufacturing capacity through the GlobalFoundries partnership announced September 9, 2026. Analyst sentiment remains overwhelmingly positive with 88% buy ratings and a $1,830 consensus price target representing 28% upside potential.

MPWR presents compelling growth exposure to AI infrastructure demand but carries premium valuation risks. The stock's 83.6 P/E ratio requires sustained high growth execution, while insider selling and competitive pressures warrant monitoring. Current technical positioning near pivot point resistance at $1,427 suggests near-term consolidation before potential breakout toward analyst targets.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.

Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MPWR
100% Buy0% Sell
Avg holding period · 25 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →